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The era of randomised studies of coronary artery bypass surgery''-7 has probably come to an end. It is, therefore, opportune to assess the present state of this form of surgery in the light of the information available from these trials.
There is general agreement that coronary artery bypass surgery is effective in relieving angina pectoris, but controversy persists as to whether it can improve prognosis. This topic has recently been extensively reviewed.'8520 Both Braunwaldl8 and Hampton'9 concluded that there is little evidence that coronary artery bypass surgery improves prognosis except in those with severe obstruction of the left main coronary artery, whereas Killip and Ryan20 consider that high risk patients with three vessel disease and reduced ventricular function may also benefit. In this review I reconsider the evidence on the effect of coronary artery bypass surgery on prognosis and discuss the practical implications.
"Natural history" of angina pectoris
Expectations of the potential effect of coronary bypass surgery on prognosis must depend on our knowledge of the natural history of ischaemic heart disease and, in particular, of angina pectoris. Current beliefs are largely rooted in the observations made on patients subjected to coronary arteriography in the 1960s. Since that time, there has been a major fall in the mortality due to ischaemic heart disease in some countries, which suggests that the baseline against which the benefits of surgery can be assessed has altered. Although coronary artery surgery itself might have provided a small contribution to this change, the mortality had started to decline before its introduction and is much greater than would be expected. Has the decline in the mortality of ischaemic heart disease been caused by a reduction in the incidence of the Requests for reprints to Professor D G Julian, Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NE7 7DN.
Accepted for publication 9 April 1985 disease or by reduced fatality rates? As yet, the answer is obscure, particularly in relation to angina, but some authorities believe that the latter is the case. Thus, Braunwald has written "it is particularly interesting to consider the steadily improving survival rate among medically treated patients with angiographically confirmed three-vessel obstructive coronary-artery disease, a condition that is now widely considered to be an indication for coronary artery bypass grafting, even though the patients are not entirely comparable. The annual mortality rate for such patients was 11*4% in the late 1960s [reported by Reeves et al], 4-8% in the early and mid 1970s (in the Veterans Administration study described by Murphy et al4), 3 -5% in the European Coronary Artery Surgery Study in the late 1970s'0 and only 2-1% in the recently reported CASS Study (sic).'5 Comparable improvements in the prognosis have occurred among medically treated patients with one or two vessel disease and normal or impaired left ventricular function."' 8 Braunwald suggests that the remarkable fall in death rate could be due to the use of beta blockers and calcium antagonists. There is, however, no evidence that calcium antagonists improve prognosis, and it is of interest that beta blockers were given to a higher proportion of the medically treated patients in the European study than in the Coronary Artery Surgery Study (CASS).
In fact, comparisons of prognosis over time, such as those above, are very misleading and it is probable that the apparent decline in the annual mortality of angina is largely spurious.2' In comparing the mortality in medical patients in the European study and in CASS, it is instructive to compare the four year survival of all (that is, non-randomised as well as randomised) medically treated patients in CASS with the medically treated patients in the European study. In patients with good left ventricular function, the findings are remarkably similar-the survival rate of 94% as opposed to 93% for two vessel disease and 82% versus 84% for three vessel disease respectively. ' '19 Ins of the data are, however, re two quite different kinds of The practical implications of the coronay arty swgery vials question that might be answered in assessing the prognostic effect of coronary bypass surgery in patients with ischaemic heart disease.
The explicative question "Does surgery improve the prognosis of patients with ischaemic heart disease in whom surgery is a reasonable option?" could be asked about the whole group of patients in whom surgery is a reasonable option or about certain defined subsets. Because of the nature of the question, it would be vital in such a study that patients do not deviate from the treatment to which they are randomised-any crossover of subjects from one to the other would contravene the concept of the study and diminish its value. This is clearly a very important question in patients for whom surgery is indicated on the basis of symptoms. If we submit a patient to surgery because of symptoms refractory to medical treatment are we improving (or worsening) his prognosis?
The pragmatic question "In patients in whom surgery is neither absolutely indicated nor absolutely contraindicated would an "aggressive" policy of immediate surgery prove superior in terms of prognosis to a "conventional" approach with medical treatment in the first place, reserving surgery for those whose symptoms demand it?" is, in essence, the question which physicians and cardiologists face in their day to day practice and to which a practical answer is required. In such a study, the crossover from medical to surgical treatment does not constitute a deviation from protocol but is merely an aspect of the conservative approach to treatment of many cardiologists.
It is highly desirable in designing a trial to state which of these two concepts lies behind it. The Veterans Administration trial was concerned with the first concept. Although it is not stated, it seems that the CASS group was also trying to answer the first question, since patients who were potential candidates for surgery on the basis of symptoms were deliberately excluded; indeed, a high proportion of patients had virtually no symptoms. Despite this, there was a very substantial crossover, which made an answer to the first question unobtainable.
The European trial, on the other hand, was very clearly and explicitly addressed to the second question. As in the CASS report, a substantial proportion of patients crossed over, but these should not be regarded as deviants from the protocol, as such a finding was foreseen and was taken into account in the trial design.
Statistical basis for trials
It is clearly desirable when setting out on a clinical trial to state the statistical principles on which the trial is based, including what number of patients is considered necessary, what reduction in mortality is expected, and what the power of the study is. The duration of the study should also be stated. In criticising the CASS and European studies, Hampton writes, "The numbers of patients in the two studies were similar. It is not clear in either case whether this number was calculated in advance as being adequate."'9 Unfortunately, Hampton does not seem to have consulted the key papers in which the basic concepts and methods of the three studies were published.3 7 12 I have been unable, from the baseline article from the Veterans Administration Study,3 to determine the statistical principles on which the size of the study was determined, only that "A sufficiently large number of patients must be studied to ensure that statistically significant differences can be evaluated in objectively identified sub-groups. In a chronic disease such as stable angina, a follow-up time of five years is desirable."
In the statistical section of the protocol of the European Multicentre Coronary Bypass Study calculations of sample size were made to take into account annual mortality rates of 2-80/o. Eventually, it was estimated that a total of approximately 700 patients was needed in the two groups7; at the outset the follow up period was defined as five years.
In the CASS report, detailed consideration was given to the expected mortality and sample size.'2 A review of available data at the time that CASS was initially designed suggested that the annual medical mortality in patients with confirmed coronary disease would be about 4%. Calculations were published estimating the statistical power of CASS to detect clinically important differences in survival for assumed annual medical mortalities of 2% and 4% respectively, and assuming a percentage reduction in mortality due to surgery of 5O0/o or 300/o respectively. Calculations were based on samples sizes of 750 and 800 patients; the follow up period was defined as five years. The number of patients entered into the European and CASS studies was, therefore, chosen in advance and successfully achieved. In the case of CASS, the mortality encountered in the medical group was much lower than that predicted so that a very much larger number of patients would have had to have been recruited to show a statistically significant result. Indeed, even if the study had shown a statistically significant difference it is doubtful whether any benefit shown could be regarded as being of clinical importance in a group with such a low mortality.
It is now generally recognised that it is desirable that the original population from which the trial patients are drawn is defined. This is a defect of the European trial, whereas in the Veterans Administra-346 tion trial the group of 1015 patients was derived from 5538 patients with stable angina who were screened and of whom 2196 were entered into the arteriographic logs. In CASS, 24 In fact a high proportion of these cases were not submitted to surgery during the succeeding five years. Information about outcome in these patients is available from registry data, but is noteworthy that their prognosis was worse than that of the class I or II patients actually included.
Baseline characteristics
The object of randomisation is to ensure a balance of important prognostic characteristics in treatment groups. In this regard each of the three studies is satisfactory, and within each study the patients allocated to medical and surgical management were similar in essential characteristics. There are, however, striking (and deliberate) differences between the studies (Table) . There are some important differences between the data provided in this Table and those shown in the apparently similar The practa mrplicatos of the coroary atey sugery tials in CASS. The CASS patients had two prognostically disadvantageous features-they had a somewhat lower ejection fraction and their criteria for arterial obstruction were more strict.
Quality of surgery
In the assessment of a surgical method of treatment, the quality of the surgery and the associated management is obviously of importance. In studies such as those reviewed here, standards equivalent to those encountered in the general run of good cardiac surgical units would be hoped for. Throughout the period of the three studies improvements were constantly taking place in several areas of surgical management. Techniques of myocardial preservation were being improved, a higher proportion of diseased vessels were being grafted, and graft patency rates were increasing. It would, therefore, be expected that mortality and morbidity would be progressively reduced, and this was, indeed, reflected in the reported results.
In the Veterans Administration study, 30 day operative mortality was 5-8%h and the vein graft patency rate at one year was 69%o. In the European study, operative mortality was 3-6% and vein graft patency was reported to be 90Yo at or before nine months and 77% between nine and 18 months. In CASS, operative mortality was 1-4%, and the number of grafts per patient was higher than in the European study. Graft patency in 129 patients assessed within 60 days was 9O0/%.
It is probable that present surgical practice in most centres corresponds fairly closely with the results reported in CASS. It is generally accepted that the mortality and the graft closure rate as well as the number of grafts used in the Veterans Administration study were such as to make the observations inapplicable to present surgical practice. Because of the unsatisfactory surgical experience in the Veterans Administration study, the rest of this review is concerned largely with the European study and CASS.
Quality of medical treatment
This is difficult to assess in the trials except in the case of beta blockers, but these drugs are almost certainly the most important in relation to prognosis. A substantially higher proportion of the patients in the European trial (74%) were receiving beta blockers at baseline than in CASS (43%), and there was higher utilisation of these drugs in "medical" patients throughout the European trial than in CASS. In both trials, approximately two thirds of "medical" patients and one third of "surgical" patients received beta blockers. (If, as some workers suggest,'8 19 beta blockers have a profound effect on prognosis, and surgery has none, it is difficult to see why in both studies the mortality in the medical groups was not lower than that in the surgical.
Results
As both the European study and CASS had a primary endpoint of five years, it seems most appropriate to consider this time interval when comparing the overall results.
In the European study, at five years 7*6% of the surgical and 16-4% of the medical cases had died-a 53% reduction in mortality (p=000025) (95% confidence interval 30-71%).10 In CASS, the risk of death was 5% for those treated surgically compared with 8% for those treated medically. The 95% confidence interval lies between a 61% reduction in mortality and a 13% increase.19 There is, therefore, an overlap in the confidence limits, meaning that the two studies are statistically compatible. If the results were pooled, as has been common practice with other trials of ischaemic heart disease, the results of statistical analysis would strongly favour surgery. As discussed by the CASS investigators, the excellent long term result in CASS patients assigned to medical treatment reduces the power of the experiment to detect a reduction in mortality afforded by prompt elective coronary artery bypass surgery. Indeed, because of the low power of the randomised section of CASS, essentially no deductions can be made about the effect of cardiac surgery on the prognosis of patients resembling those included (or indeed any other patients).
Subset analysis
As is often pointed out by the critics of controlled trials, there are dangers in subset analysis, particularly if these are defined retrospectively. When subsets have been defined in advance as an intrinsic part of the study they are valid provided that the appropriate statistical considerations are respected.
The subset finding that has been most widely accepted is that from the Veterans Administration study in which a significant reduction in mortality was observed in patients with disease of the left main coronary artery.' The four year mortality in the 44 patients treated medically was 33% compared with 7% in 46 patients treated surgically. The numbers studied were small, and the confidence limits of this finding were wide. None the less, it has achieved widespread acceptance because of confirmatory evidence from other sources.
In In CASS no subsets appeared to benefit from surgical intervention at five years but analysis after a further 14 months of follow-up revealed a significantly greater survival rate in surgically assigned patients with three vessel disease and impaired ventricular function (p<0.01).20
Summary of the trials
All three studies were well designed and used expert statistical advice. The chief defect of the European study was the absence of information about the original population from which the trial patients were drawn. The major defect of the CASS randomisation trial was its low power because of the randomisation of a number of patients which proved to be too small because of the low mortality of the control group.
The striking differences in prognosis of the medically treated patients can be accounted for by their different baseline characteristics rather than by progressively improving medical prognosis '8 The practical ivnpicatio of the coronwy wwy sugery vial3 terms of symptoms. For example, in the United States angina which prevented a patient, of whatever age, from playing golf would be considered unacceptable and regarded as an indication for surgery. By contrast, in other countries the cardiologist weighs up the patient very carefully before considering operative intervention and, consciously or subconsciously, takes into account such factors as age, occupation, employability, and life style. Many patients come into a borderline zone, and in these the physician attempts, as far as he can, to avoid surgery in the hope that time or modifications in medical treatment will achieve a situation that is tolerable, if not ideal. It is particularly in such patients that knowledge about the effect of surgery on prognosis is relevant, as the probability of an improvement in life expectancy would often tip the balance in favour of a surgical as opposed to a medical approach. This poses a particular problem for the physician in district hospitals who does not have immediate access to coronary arteriography.
When all the evidence is put together, there is little to indicate the need for coronary arteriography in the patient who has never had symptoms that are more than mild and who performs an exercise test with little difficulty. On the other hand, those who have had more severe symptoms, or who have adverse features on an exercise test (such as a low exercise work capacity, readily induced ST depression of >0. 1 mV, or a fall in ejection fraction) should be assessed by coronary arteriography. If this investigation shows three vessel disease or two vessel disease with a very proximal left anterior descending lesion, coronary artery bypass surgery should be seriously considered. Clearly, factors such as age and the attitude of the patient must be taken into account in deciding on investigation or surgery.
The future
Changes are taking place in the management of ischaemic heart disease that may alter these conclusions.
The introduction of new drugs and improvements in methods of managing life style could reduce the mortality in medically treated patients. As yet, there is no evidence that calcium antagonists improve prognosis, and there is no proof that risk factor control, other than the cessation of smoking, improves life expectancy.
The development of coronary angioplasty is clearly an important new factor in the management of angina pectoris. As yet, its effect on prognosis has not been established.
Changes are also taking place in the surgical management of coronary disease. In particular, techniques of myocardial preservation have resulted in much better results in patients with low ejection fraction. Another important development has been the increasing use of internal mammary artery implants. Evidence suggests that graft patency rates are higher and the long term results are better with this technique than with saphenous vein bypass surgery.
Conclusion
We can be reasonably confident that surgery improves prognosis in certain groups of patients with ischaemic heart disease. The ones most likely to benefit are those with disease of the left main coronary artery and those with three vessel disease or two vessel disease in which the proximal left anterior descending artery is involved. Coronary-arteriography alone, however, provides an inadequate guide to prognosis, as it seems that surgery is most helpful when such anatomical features are accompanied by evidence of left ventricular dysfunction at rest or on exercise.
Physicians should consider the possible -beneficial effects of surgery on prognosis in all patients with angina. In doing so, they should take into account symptoms and non-invasive indices of left ventricular function, particularly response to exercise. If these features indicate a substantially worsened prognosis, coronary arteriography should be undertaken if a surgical approach seems a reasonable option. 
